Uncategorized
Inflammasome Therapeutics Announces Topline 3-month Data from a Clinical Trial of its First-in-Class Dual Inflammasome Inhibitor, K8, in Geographic Atrophy, Demonstrating Rapid, Substantial and Significant Efficacy and Safety
NEWTON, Mass.--(BUSINESS WIRE)-- #NRTIs--First-in-class dual inflammasome inhibitor demonstrates rapid, substantial and significant efficacy, and safety in 3 mo. trial in geographic atrophy